From O’Shaughnessy to opportunity: innovating Hepatology Trials in the UK
- 13 July 2024
- journal article
- review article
- Published by BMJ in Frontline Gastroenterology
- Vol. 15 (5) , 395-400
Abstract
Developing new treatments that improve outcomes for patients with decompensated cirrhosis remains an unmet area of clinical need. The UK has a rich history of being on the forefront of clinical trials for this patient group. However, there have been challenges in achieving this goal in the past decade, with several negative studies as well as trials struggling to achieve recruitment. This has been further exacerbated by the changed clinical landscape following the COVID-19 pandemic. In response to this, the O’Shaughnessy report was commissioned to identify potential opportunities to improve clinical trial performance in the UK. In this review article, we identify critical areas for the UK hepatology community to collaborate and develop sustainable partnerships for clinical trial delivery which will ensure that outcomes are representative, inclusive and patient-centred.Keywords
Funding Information
- National Institute for Health and Care Research (NIHR155694)
This publication has 12 references indexed in Scilit:
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisNew England Journal of Medicine, 2024
- A Tutorial on Modern Bayesian Methods in Clinical TrialsTherapeutic Innovation & Regulatory Science, 2023
- Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trialHepatology, 2023
- A Randomized Trial of Albumin Infusions in Hospitalized Patients with CirrhosisNew England Journal of Medicine, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT ConsortiumAlcohol, Clinical and Experimental Research, 2017
- Prednisolone or Pentoxifylline for Alcoholic HepatitisNew England Journal of Medicine, 2015
- Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitisThe Lancet, 2014
- Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure TrialThe American Journal of Cardiology, 2014
- Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic HepatitisQJM: An International Journal of Medicine, 1971